NEUMOLOGÍA PEDIÁTRICA

23 / 50

21 Contenido disponible en
aquired pneumonia due to methicillin-resistant an methicillin
susceptible Staphylococcus aureus producing the Panton-Valentine
Leukocidin. Int J Tuberc Lung Dis 2009; 13: 1476-85.
20. Chickering HT, Park JH. Staphylococcus aureus pneumonia. JAMA
1919; 72: 617-26.
21. Adam H, McGeer A, Simor A. Fatal case of post-influenza,
community associated MRSA pneumonia in an Ontario teenager
with subsequent familial transmission. Can Commun Dis Rep
2007; 33: 45-8.
22. Connor E, Powell K. Fulminant pneumonia caused by concomitant
infection with influenza B virus and Staphylococcus aureus. J Pediatr
1985; 106: 447-50.
23. Tong HH, McIver MA, Fisher LM, DeMaria TF. Effect of lacto-
N-neotetraose, asialoganglioside-GM1 and neuraminidase on
adherence of otitis media-associated serotypes of Streptococcus
pneumoniae to chinchilla tracheal epithelium. Microb Pathog 1999;
26: 111-19.
24. LaMarco KL, Diven WF, Glew RH. Experimental alteration of
chinchilla middle ear mucosae by bacterial neuraminidase. Ann
Otol Rhinol Laryngol 1986; 95: 304-8.
25. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO. Invol­
vement of Panton-Valentine leukocidinproducing Staphylococcus
aureus in primary skin infections and pneumonia. Clin Infect
Dis1999; 29: 1128 -32.
26. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF. Presence
of genes encoding the Panton-Valentine leukocidin exotoxin is not
the primary determinant of outcome in patients with complicated
skin and skin structure infections due to methicillin- resistant
Staphylococcus aureus: results of a multinational trial. J Clin
Microbiol 2009; 47: 3952-7.
27. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME.
Genotypic characteristics of Staphylococcus aureus isolates from a
multinational trial of complicated skin and skin structure infections.
J Clin Microbiol 2008; 46: 678-84.
28. Campo M, Hachem R, Jiang Y, Dvorak T, Carrillo-Marquez M.
Panton Valentine leukocidin exotoxin has no effect on the outcome
of cancer patients with methicillin-resistant Staphylococcus aureus
(MRSA) infections. Medicine (Baltimore) 2011; 90: 312-8.
29. Hensler T, König B, Prévost G, Piémont Y, Köller M. Leukotriene
B4 generation and DNA fragmentation induced by leukocidin from
Staphylococcus aureus: protective role of granulocyte-macrophage
colony-stimulating factor (GM-CSF) and GCSF for human
neutrophils. Infect Immun 1994; 62: 2529-35.
30. Konig B, Prevost G, Piemont Y, Konig W. Effects of Staphylococcus
aureus leukocidins on inflammatory mediator release from human
granulocytes. J Infect Dis 1995; 171: 607-13.
31. Pauline Yoong, Gerald B. Pier. Outcome in a Model of Methicillin-
Resistant Panton-Valentine Leukocidin Improve the Immune. Infect
Immun 2012; 80: 2894-904.
32. Bradley JS. Management of community acquired pediatric
pneumonia in an era of increasing antibiotic resistance. Pediatr
Infect Dis J 2002; 21: 592-8.
33. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C. Impact
of BAL data on the therapy and outcome of ventilator-associated
pneumonia. Chest 1997; 111: 676-85.
34. Kyra A. Len, Lora Bergert, Shilpa Patel, Marian Melish, Chieko
Kimata, Guliz Erdem, Community-Acquired Staphylococcus aureus
Pneumonia Among Hospitalized Children in Hawaii. Pediatr
Pulmonol 2010; 45: 898-905.
35. Catherine Liu, Arnold Bayer, Sara E. Cosgrove, Robert S. Daum.
Clinical Practice Guidelines by the Infectious Diseases Society of
America for the Treatment of Methicillin-Resistant Staphylococcus
aureus Infections in Adults and Children. Clin Infect Dis 2011; 52:
285-92.
36. Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and
tolerability of linezolid in pediatric patients: a systematic review.
ClinTher 2010; 32: 66-88.
37. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al;
Linezolid Pediatric Study Group. Linezolid versus vancomycin for
treatment of resistant Gram-positive infections in children. Pediatr
Infect Dis J 2003; 22: 677-86.
38. Consenso de la Sociedad Latinoamericana de Infectología Pediátrica
(SLIPE). Neumonía Adquirida en la Comunidad (NAC). www.slipe.
org/.../ConsensoNACninosSLIPE_8sept2010.
39. American Academy of Pediatrics.Staphylococcal Infections. In: Red
Book 2006 Report of the Committee Twenty-seventh Edition.
Pickering LK, Baker CJ, Long SS (Eds).Elk Grove Village, IL, on
Infectious Diseases American Academy of Pediatrics, 2006, 603.
40. Micek ST. Alternatives to vancomycin for the treatment of
methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis
2007; 45: S184-S190.
41. Appelbaum PC. The emergence of vancomycin-intermediate and
vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect
2006;12(Suppl. 1): 16-23.
42. Linares J. The VISA/GISA problem: therapeutic implications. Clin
Microbiol Infect 2001; 7(Suppl. 4): 8-15.
43. CDC. Vancomycin-resistant Staphylococcus aureus- New York,
2004. MMWR 2004; 53: 322-3.
Neumonía secundaria a Staphylococcus aureus resistente a la meticilina - E. Kassisse et al Neumol Pediatr 2013; 8 (1): 17-21.